Table 2 Diabetes medication by gender and prevalent coronary heart disease

Number of diabetes medication (mean, STD*)

1.3 (1.1)

1.3 (1.2)

1.5 (1.3)

1.4 (1.1)

1.3 (1.1)

1.2 (1.2)

Number of diabetes medication

0

138

22.3

158

30.4

27

18.5

15

22.7

111

23.5

143

31.6

1

245

39.6

175

33.7

50

34.3

22

33.3

195

41.2

153

33.8

2

159

25.7

113

21.8

46

31.5

17

25.8

113

23.9

96

21.2

3 and more

77

12.4

73

14.1

23

15.7

12

18.2

54

11.4

61

13.5

Biguanide

343

55.0

273

52.3

70

47.6

35

52.2

273

57.2

238

52.3

Sulfonylurea

132

21.2

92

17.6

32

21.8

14

20.9

100

21.0

78

17.1

Alpha-glucosidase inhibitor

14

2.2

13

2.5

5

3.4

1

1.5

9

1.9

12

2.6

Thiazolidinedione

39

6.3

19

3.6

11

7.5

3

4.5

28

5.9

16

3.5

Glinide

21

3.4

13

2.5

6

4.1

1

1.5

15

3.1

12

2.6

Glucagon-like peptide-I analogue (GLP-I) exenatide

6

1.0

5

1.0

4

2.7

0

0

2

0.4

5

1.1

Dipeptidyl peptidase-4 (DPP-4) inhibitor

20

3.2

28

5.4

7

3.3

4

6.0

17

3.6

24

5.3

Oral combination drug

26

4.2

9

1.7

6

4.1

1

1.5

20

4.2

8

1.8

Insulin treatment

123

19.8

107

20.5

43

29.7

20

29.8

80

16.8

87

19.1

Short acting insulin

47

7.5

40

7.7

16

10.9

7

10.4

31

6.5

33

7.3

Intermediate acting (basal insulin)

53

8.5

56

10.7

19

12.9

10

14.9

34

7.1

46

10.1

Human insulin combination (short and intermediate acting)

22

3.5

14

2.7

8

5.4

4

6.0

14

2.9

10

2.2

Insulin analogue

58

9.3

43

8.2

22

15.0

8

11.9

36

7.5

35

7.7